Protalix BioTherapeutics Inc (PLX)
1.14
-0.03
(-2.56%)
USD |
NYAM |
May 17, 16:00
1.145
0.00 (0.00%)
After-Hours: 20:00
Protalix BioTherapeutics Cash from Financing (TTM): 10.43M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 10.43M |
December 31, 2023 | 24.67M |
September 30, 2023 | 28.74M |
June 30, 2023 | 30.26M |
March 31, 2023 | 22.47M |
December 31, 2022 | 8.238M |
September 30, 2022 | 0.117M |
June 30, 2022 | -27.39M |
March 31, 2022 | -30.04M |
December 31, 2021 | 12.08M |
September 30, 2021 | 20.78M |
June 30, 2021 | 51.24M |
March 31, 2021 | 49.97M |
December 31, 2020 | 46.47M |
September 30, 2020 | |
June 30, 2020 | |
March 31, 2020 | |
December 31, 2019 | |
September 30, 2019 | |
June 30, 2019 | |
March 31, 2019 | |
December 31, 2018 | |
September 30, 2018 | |
June 30, 2018 | |
March 31, 2018 |
Date | Value |
---|---|
December 31, 2017 | -1.419M |
September 30, 2017 | 18.28M |
June 30, 2017 | 8.734M |
March 31, 2017 | 12.97M |
December 31, 2016 | |
September 30, 2016 | |
June 30, 2016 | |
March 31, 2016 | |
December 31, 2015 | |
September 30, 2015 | |
June 30, 2015 | |
March 31, 2015 | |
December 31, 2014 | 0.046M |
September 30, 2014 | -0.025M |
June 30, 2014 | 66.89M |
March 31, 2014 | 66.92M |
December 31, 2013 | |
September 30, 2013 | |
June 30, 2013 | |
March 31, 2013 | |
December 31, 2012 | 26.56M |
September 30, 2012 | 26.44M |
June 30, 2012 | 26.58M |
March 31, 2012 | 25.56M |
December 31, 2011 | 20.93M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-30.04M
Minimum
Mar 2022
51.24M
Maximum
Jun 2021
17.72M
Average
21.62M
Median
Cash from Financing (TTM) Benchmarks
Agenus Inc | 78.45M |
InfuSystems Holdings Inc | -7.084M |
AIM ImmunoTech Inc | 0.485M |
Perspective Therapeutics Inc | 167.19M |
Armata Pharmaceuticals Inc | 59.32M |